サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1539340

糖尿病性腎症市場：世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年

Diabetic Nephropathy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日: | 発行: Persistence Market Research | ページ情報: 英文 213 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
糖尿病性腎症市場：世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年
出版日: 2024年08月20日
発行: Persistence Market Research
ページ情報: 英文 213 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の糖尿病性腎症市場に関する詳細な調査レポートを出版し、市場促進要因・動向・機会・課題などの市場力学に関する詳細な洞察を提供しました。当レポートは、ヘルスケアおよび製薬部門に携わる利害関係者向けに、市場構造と将来展望の包括的な理解を提供することを目的としています。

主な洞察

  • 世界市場収益（2022年）：27億米ドル
  • 推定市場価値（2033年）：49億米ドル
  • 世界市場成長率（CAGR 2022-2033）：6.8%

糖尿病性腎症の世界市場- レポート範囲：

糖尿病性腎症市場は、糖尿病の重篤な合併症である糖尿病性腎症（DKD）の管理を目的とした医薬品および治療法の開発、生産、流通に焦点を当てています。この市場を牽引しているのは、世界の糖尿病罹患率の増加であり、それに伴い糖尿病性腎症の罹患率も上昇しています。この市場には、ACE阻害薬、ARB、糖尿病患者の腎障害の進行を遅らせるその他の薬剤など、さまざまな製品が含まれています。

市場成長の促進要因：

糖尿病患者の増加

糖尿病性腎症は糖尿病の主要な合併症であり、世界の糖尿病有病率の上昇に伴い、糖尿病性腎症の発症率も増加しています。糖尿病性腎症は末期腎不全の主要な原因であり、糖尿病患者は糖尿病でない患者に比べてこの病態を発症する可能性が10倍高いです。糖尿病患者の数が増え続けるにつれ、糖尿病性腎症を管理するための効果的な治療や介入に対する需要も増加し、市場の成長を牽引しています。

意識の高まりと早期診断

糖尿病とその合併症に伴うリスクに対する認識が高まるにつれ、糖尿病性腎症の早期診断と管理が増加しています。ヘルスケアプロバイダーは、糖尿病患者の腎障害の定期的なスクリーニングに注力しており、これが早期介入と患者の転帰の改善につながっています。このような積極的なアプローチは、糖尿病性腎症市場の成長をさらに促進すると予想されます。

市場の課題

高い治療費

糖尿病性腎症の治療費が高いことが、市場成長の大きな障壁となっています。糖尿病性腎症（DKD）患者は、合併症のない糖尿病患者に比べて医療費が大幅に高いです。NCBIに掲載された「Direct medical cost of nephropathy in patients with type 2 diabetes-International Urology and Nephrology」と題する研究によると、DKD患者の推定医療費は603ドル（283-1267）ドルであったのに対し、合併症のない糖尿病患者の推定医療費は222ドル（141-292）ドルでした。このような費用格差は、特に安価なヘルスケアへのアクセスが制限されている低所得国において、経済的負担をもたらす可能性があります。

限られた治療選択肢と専門知識の不足

低所得国や後発開発途上国では、糖尿病性腎症治療の計画や資源が不十分であり、訓練を受けた専門医の不足も相まって、大きな課題となっています。さらに、糖尿病性腎症に対する完全な治療法は現在のところ存在せず、既存の薬物療法は疾患の管理または進行遅延に役立つのみです。これらの制約は、世界の糖尿病性腎症市場の大きな抑制要因となっています。

本レポートで扱う主な質問

  • 世界の糖尿病性腎症市場の成長を促進する主な要因は何か？
  • 糖尿病性腎症治療の採用をリードしている消費者層は？
  • 医学研究と治療法の進歩は競合情勢にどのような影響を与えているか？
  • 世界の糖尿病性腎症市場における主要プレイヤーは誰で、市場ポジションを維持するためにどのような戦略を採用しているのか？
  • 世界の糖尿病性腎症市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 製品イノベーション/開発動向

第4章 重要成功要因

  • 製品採用分析
  • 疾病疫学
  • 規制状況
  • パイプライン評価
  • PESTEL分析
  • ポーターの分析
  • バリューチェーン分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤クラス別
    • 糖尿病別
    • 投与経路別
    • 流通チャネル別
    • 地域別
  • 2024年の市場シナリオ

第7章 世界市場の需要（金額）分析

  • 市場（金額）分析、2019～2023年
  • 市場（金額）予測、2024～2033年
    • 前年比成長動向分析
    • 絶対的収益機会

第8章 薬剤クラス別：世界市場分析

  • イントロダクション/主な調査結果
  • 市場規模（金額）分析、2019～2023年
  • 市場規模（金額）分析と予測、2024～2033年
    • 利尿剤
    • アンジオテンシン受容体遮断薬
    • アンジオテンシン変換酵素阻害剤（ACE阻害剤）
    • ナトリウム-グルコース輸送タンパク質2（SGLT2）阻害剤
    • その他
  • 薬剤クラス別の市場の魅力分析

第9章 糖尿病別：世界市場分析

  • イントロダクション/主な調査結果
  • 市場規模（金額）分析、2019～2023年
  • 市場規模（金額）分析と予測、2024～2033年
    • 1型糖尿病
    • 2型糖尿病
  • 糖尿病別市場の魅力分析

第10章 投与経路別：世界市場分析

  • イントロダクション/主な調査結果
  • 市場規模（金額）分析、2019～2023年
  • 市場規模（金額）分析と予測、2024～2033年
    • 経口
    • 非経口
    • その他
  • 投与経路別の市場の魅力分析

第11章 流通チャネル別：世界市場分析

  • イントロダクション/主な調査結果
  • 市場規模（金額）分析、2019～2023年
  • 市場規模（金額）分析と予測、2024～2033年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他
  • 投与経路別の市場の魅力分析

第12章 地域別：世界市場分析

  • イントロダクション
  • 市場規模（金額）分析、2019～2023年
  • 市場規模（金額）分析と予測、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ（中東・アフリカ）
  • 地域別市場の魅力分析

第13章 北米市場分析

第14章 ラテンアメリカ市場分析

第15章 欧州市場分析

第16章 東アジア市場分析

第17章 南アジア市場分析

第18章 オセアニア市場

第19章 中東・アフリカ市場分析

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • AstraZeneca（UK.）
    • Pfizer Inc（US.）
    • Allergan, Inc（Ireland）
    • Bristol-Myers Squibb Company（US.）
    • Endo International plc（Ireland）
    • Dr. Reddy's Laboratories Ltd（India）
    • Sun Pharmaceutical Industries Ltd（India）
    • Teva Pharmaceutical Industries Ltd（Israel）
    • Novartis AG（Switzerland）
    • Eli Lilly and Company（India）
    • Mylan NV（US.）
    • Cipla Inc（India）
    • Lupin（India）
    • Aurobindo Pharma（India）
    • Sanofi（France）
    • Fresenius SE &Co. KGaA（Germany）
    • F. Hoffmann-La Roche Ltd（Switzerland）
    • Takeda Pharmaceutical Company Limited（Japan）
    • Abbott（US.）

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP3594

Persistence Market Research has recently published an in-depth report on the global diabetic nephropathy market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, catering to stakeholders involved in the healthcare and pharmaceutical sectors.

Key Insights:

  • Global Market Revenue (2022): US$ 2.7 Billion
  • Estimated Market Value (2033): US$ 4.9 Billion
  • Global Market Growth Rate (CAGR 2022-2033): 6.8%

Global Diabetic Nephropathy Market - Report Scope:

The diabetic nephropathy market is focused on the development, production, and distribution of medications and treatments aimed at managing diabetic kidney disease (DKD), a serious complication of diabetes mellitus. The market is driven by the increasing prevalence of diabetes worldwide, which in turn is escalating the incidence of diabetic nephropathy. This market encompasses a range of products, including ACE inhibitors, ARBs, and other medications that slow the progression of kidney damage in diabetic patients.

Market Growth Drivers:

Rising Prevalence of Diabetic Patients

Diabetic nephropathy is a major complication of diabetes mellitus, and with the rising global prevalence of diabetes, the incidence of diabetic nephropathy is also increasing. Diabetic nephropathy is a leading cause of end-stage renal failure, with patients having diabetes mellitus being 10 times more likely to develop this condition compared to those without diabetes. As the number of diabetic patients continues to rise, so does the demand for effective treatments and interventions to manage diabetic nephropathy, driving the market growth.

Increasing Awareness and Early Diagnosis

With growing awareness of the risks associated with diabetes and its complications, there has been an increase in early diagnosis and management of diabetic nephropathy. Healthcare providers are focusing on regular screening of diabetic patients for kidney damage, which has led to early intervention and improved patient outcomes. This proactive approach is expected to further fuel the growth of the diabetic nephropathy market.

Market Challenges:

High Cost of Treatment

The high cost of treating diabetic nephropathy is a significant barrier to market growth. Patients with diabetic kidney disease (DKD) incur substantially higher medical costs compared to those with diabetes but without complications. According to a study published in NCBI titled "Direct medical cost of nephropathy in patients with type 2 diabetes - International Urology and Nephrology," the estimated cost for a patient with DKD was $603 (283-1267) USD, compared to $222 (141-292) USD for a diabetic patient without complications. This cost disparity can result in financial strain, particularly in low-income countries where access to affordable healthcare is limited.

Limited Treatment Options and Lack of Expertise

In low-income and less developed countries, inadequate planning and resources for diabetic nephropathy therapy, coupled with a shortage of trained specialists, present significant challenges. Moreover, there is currently no complete cure for diabetic nephropathy; existing medications only help in managing or delaying the progression of the disease. These limitations are major restraints on the global diabetic nephropathy market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global diabetic nephropathy market?
  • Which consumer segments are leading the adoption of diabetic nephropathy treatments?
  • How are advancements in medical research and treatment methods influencing the competitive landscape?
  • Who are the key players in the global diabetic nephropathy market, and what strategies are they employing to maintain their market position?
  • What are the emerging trends and future prospects in the global diabetic nephropathy market?

Competitive Intelligence and Business Strategy:

Leading players in the global diabetic nephropathy market, such as Abbott Laboratories, Bayer AG, and Novartis AG, are focusing on research and development, strategic collaborations, and expanding their product portfolios to maintain a competitive edge. These companies are investing in the development of novel therapies that can better manage the progression of diabetic nephropathy. Additionally, collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of new treatment protocols. Leveraging digital platforms to increase awareness and patient engagement is also a key strategy to strengthen market positioning.

Key Companies Profiled:

  • AstraZeneca (UK.)
  • Pfizer Inc (US.)
  • Allergan, Inc (Ireland)
  • Bristol-Myers Squibb Company (US.)
  • Endo International plc (Ireland)
  • Dr. Reddy's Laboratories Ltd (India)
  • Sun Pharmaceutical Industries Ltd (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (India)
  • Mylan NV (US.)
  • Cipla Inc (India)
  • Lupin (India)
  • Aurobindo Pharma (India)
  • Sanofi (France)
  • Fresenius SE & Co. KGaA (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Abbott (US.)

Key Segments Covered in Diabetic Nephropathy Industry Research

Drug Class:

  • Diuretics
  • Angiotensin Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  • Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  • Others

Diabetes Type:

  • Type-1 Diabetes
  • Type-2 Diabetes

Route of Administration:

  • Oral
  • Parenteral
  • Others

Distribution Channel:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Disease Epidemiology
  • 4.3. Regulatory Landscape
  • 4.4. Pipeline Assessment
  • 4.5. PESTEL Analysis
  • 4.6. Porter's Analysis
  • 4.7. Value Chain Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Renal Disease Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Development of Novel Drugs
    • 5.2.2. Regulatory Impositions
    • 5.2.3. Increasing Spending on Research and Development
    • 5.2.4. Increasing Pipeline of Therapeutic Drugs
    • 5.2.5. Rising Product Approvals
    • 5.2.6.Growing Diabetes and Obesity Populations
    • 5.2.7. Strategic Mergers and Acquisitions Among Local manufacturers
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug Class
    • 6.1.2. By Diabetes
    • 6.1.3. By Route of Administration
    • 6.1.4. By Distribution Channel
    • 6.1.5. By Region
  • 6.2. 2024 Market Scenario

7. Global Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis, by Drug Class, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Drug Class, 2024-2033
    • 8.3.1. Diuretics
    • 8.3.2. Angiotensin Receptor Blockers
    • 8.3.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
    • 8.3.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Drug Class

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Diabetes

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Diabetes, 2024-2033
    • 9.3.1. Type-1 Diabetes
    • 9.3.2. Type-2 Diabetes
  • 9.4. Market Attractiveness Analysis, by Diabetes

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Attractiveness Analysis, by Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channels

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
    • 11.3.4. Others
  • 11.4. Market Attractiveness Analysis, by Route of Administration

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. East Asia
    • 12.3.5. South Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa (MEA)
  • 12.4. Market Attractiveness Analysis, by Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Class
    • 13.3.3. By Diabetes
    • 13.3.4. By Route of Administration
    • 13.3.5. By Distribution Channels
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Diabetes
    • 13.4.4. By Route of Administration
    • 13.4.5. By Distribution Channels
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Diabetes
        • 13.8.1.2.3. By Route of Administration
        • 13.8.1.2.4. By Distribution Channels
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Diabetes
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channels

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. Mexico
      • 14.3.1.2. Brazil
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Class
    • 14.3.3. By Diabetes
    • 14.3.4. By Route of Administration
    • 14.3.5. By Distribution Channels
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Diabetes
    • 14.4.4. By Route of Administration
    • 14.4.5. By Distribution Channels
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Mexico Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Diabetes
        • 14.8.1.2.3. By Route of Administration
        • 14.8.1.2.4. By Distribution Channels
    • 14.8.2. Brazil Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Diabetes
        • 14.8.2.2.3. By Route of Administration
        • 14.8.2.2.4. By Distribution Channels
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Diabetes
        • 14.8.3.2.3. By Route of Administration
        • 14.8.3.2.4. By Distribution Channels

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. Italy
      • 15.3.1.3. France
      • 15.3.1.4. U.K.
      • 15.3.1.5. Spain
      • 15.3.1.6. BENELUX
      • 15.3.1.7. Russia
      • 15.3.1.8. Nordic Countries
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Drug Class
    • 15.3.3. By Diabetes
    • 15.3.4. By Route of Administration
    • 15.3.5. By Distribution Channels
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Diabetes
    • 15.4.4. By Route of Administration
    • 15.4.5. By Distribution Channels
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Diabetes
        • 15.8.1.2.3. By Route of Administration
        • 15.8.1.2.4. By Distribution Channels
    • 15.8.2. Italy Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Diabetes
        • 15.8.2.2.3. By Route of Administration
        • 15.8.2.2.4. By Distribution Channels
    • 15.8.3. France Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Diabetes
        • 15.8.3.2.3. By Route of Administration
        • 15.8.3.2.4. By Distribution Channels
    • 15.8.4. U.K. Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Diabetes
        • 15.8.4.2.3. By Route of Administration
        • 15.8.4.2.4. By Distribution Channels
    • 15.8.5. Spain Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.5.2.1. By Drug Class
        • 15.8.5.2.2. By Diabetes
        • 15.8.5.2.3. By Route of Administration
        • 15.8.5.2.4. By Distribution Channels
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.6.2.1. By Drug Class
        • 15.8.6.2.2. By Diabetes
        • 15.8.6.2.3. By Route of Administration
        • 15.8.6.2.4. By Distribution Channels
    • 15.8.7. Russia Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.7.2.1. By Drug Class
        • 15.8.7.2.2. By Diabetes
        • 15.8.7.2.3. By Route of Administration
        • 15.8.7.2.4. By Distribution Channels
    • 15.8.8. Nordic Countries Market Analysis
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast, by Market Taxonomy
        • 15.8.8.2.1. By Drug Class
        • 15.8.8.2.2. By Diabetes
        • 15.8.8.2.3. By Route of Administration
        • 15.8.8.2.4. By Distribution Channels

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Class
    • 16.3.3. By Diabetes
    • 16.3.4. By Route of Administration
    • 16.3.5. By Distribution Channels
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Drug Class
    • 16.4.2. By Diabetes
    • 16.4.3. By Route of Administration
    • 16.4.4. By Distribution Channels
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Diabetes
        • 16.8.1.2.3. By Route of Administration
        • 16.8.1.2.4. By Distribution Channels
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Diabetes
        • 16.8.2.2.3. By Route of Administration
        • 16.8.2.2.4. By Distribution Channels
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 16.8.3.2.1. By Drug Class
        • 16.8.3.2.2. By Diabetes
        • 16.8.3.2.3. By Route of Administration
        • 16.8.3.2.4. By Distribution Channels

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Malaysia
      • 17.3.1.4. Thailand
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Drug Class
    • 17.3.3. By Diabetes
    • 17.3.4. By Route of Administration
    • 17.3.5. By Distribution Channels
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Diabetes
    • 17.4.4. By Route of Administration
    • 17.4.5. By Distribution Channels
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Diabetes
        • 17.8.1.2.3. By Route of Administration
        • 17.8.1.2.4. By Distribution Channels
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Diabetes
        • 17.8.2.2.3. By Route of Administration
        • 17.8.2.2.4. By Distribution Channels
    • 17.8.3. Malaysia Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Diabetes
        • 17.8.3.2.3. By Route of Administration
        • 17.8.3.2.4. By Distribution Channels
    • 17.8.4. Thailand Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Diabetes
        • 17.8.4.2.3. By Route of Administration
        • 17.8.4.2.4. By Distribution Channels

18. Oceania Market 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Class
    • 18.3.3. By Diabetes
    • 18.3.4. By Route of Administration
    • 18.3.5. By Distribution Channels
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug Class
    • 18.4.3. By Diabetes
    • 18.4.4. By Route of Administration
    • 18.4.5. By Distribution Channels
  • 18.5. Key Market Participants - Intensity Mapping
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.1.2.1. By Drug Class
        • 18.8.1.2.2. By Diabetes
        • 18.8.1.2.3. By Route of Administration
        • 18.8.1.2.4. By Distribution Channels
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 18.8.2.2.1. By Drug Class
        • 18.8.2.2.2. By Diabetes
        • 18.8.2.2.3. By Route of Administration
        • 18.8.2.2.4. By Distribution Channels

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkiye
      • 19.3.1.3. South Africa
      • 19.3.1.4. North Africa
      • 19.3.1.5. Rest of Middle East and Africa
    • 19.3.2. By Drug Class
    • 19.3.3. By Diabetes
    • 19.3.4. By Route of Administration
    • 19.3.5. By Distribution Channels
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Drug Class
    • 19.4.2. By Diabetes
    • 19.4.3. By Route of Administration
    • 19.4.4. By Distribution Channels
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.1.2.1. By Drug Class
        • 19.8.1.2.2. By Diabetes
        • 19.8.1.2.3. By Route of Administration
        • 19.8.1.2.4. By Distribution Channels
    • 19.8.2. Turkiye Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.2.2.1. By Drug Class
        • 19.8.2.2.2. By Diabetes
        • 19.8.2.2.3. By Route of Administration
        • 19.8.2.2.4. By Distribution Channels
    • 19.8.3. South Africa Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.3.2.1. By Drug Class
        • 19.8.3.2.2. By Diabetes
        • 19.8.3.2.3. By Route of Administration
        • 19.8.3.2.4. By Distribution Channels
    • 19.8.4. North Africa Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
        • 19.8.4.2.1. By Drug Class
        • 19.8.4.2.2. By Diabetes
        • 19.8.4.2.3. By Route of Administration
        • 19.8.4.2.4. By Distribution Channels

20. Market Structure Analysis

  • 20.1. Market Analysis, by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. AstraZeneca (UK.)
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financials
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Strategy Overview
        • 21.3.1.6.1. Marketing Strategy
        • 21.3.1.6.2. Product Strategy
        • 21.3.1.6.3. Channel Strategy
    • 21.3.2. Pfizer Inc (US.)
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financials
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Strategy Overview
        • 21.3.2.6.1. Marketing Strategy
        • 21.3.2.6.2. Product Strategy
        • 21.3.2.6.3. Channel Strategy
    • 21.3.3. Allergan, Inc (Ireland)
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financials
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Strategy Overview
        • 21.3.3.6.1. Marketing Strategy
        • 21.3.3.6.2. Product Strategy
        • 21.3.3.6.3. Channel Strategy
    • 21.3.4. Bristol-Myers Squibb Company (US.)
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financials
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Strategy Overview
        • 21.3.4.6.1. Marketing Strategy
        • 21.3.4.6.2. Product Strategy
        • 21.3.4.6.3. Channel Strategy
    • 21.3.5. Endo International plc (Ireland)
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financials
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Strategy Overview
        • 21.3.5.6.1. Marketing Strategy
        • 21.3.5.6.2. Product Strategy
        • 21.3.5.6.3. Channel Strategy
    • 21.3.6. Dr. Reddy's Laboratories Ltd (India)
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financials
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Strategy Overview
        • 21.3.6.6.1. Marketing Strategy
        • 21.3.6.6.2. Product Strategy
        • 21.3.6.6.3. Channel Strategy
    • 21.3.7. Sun Pharmaceutical Industries Ltd (India)
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financials
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Strategy Overview
        • 21.3.7.6.1. Marketing Strategy
        • 21.3.7.6.2. Product Strategy
        • 21.3.7.6.3. Channel Strategy
    • 21.3.8. Teva Pharmaceutical Industries Ltd (Israel)
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financials
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Strategy Overview
        • 21.3.8.6.1. Marketing Strategy
        • 21.3.8.6.2. Product Strategy
        • 21.3.8.6.3. Channel Strategy
    • 21.3.9. Novartis AG (Switzerland)
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financials
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Strategy Overview
        • 21.3.9.6.1. Marketing Strategy
        • 21.3.9.6.2. Product Strategy
        • 21.3.9.6.3. Channel Strategy
    • 21.3.10. Eli Lilly and Company (India)
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financials
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Strategy Overview
        • 21.3.10.6.1. Marketing Strategy
        • 21.3.10.6.2. Product Strategy
        • 21.3.10.6.3. Channel Strategy
    • 21.3.11. Mylan NV (US.)
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financials
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Strategy Overview
        • 21.3.11.6.1. Marketing Strategy
        • 21.3.11.6.2. Product Strategy
        • 21.3.11.6.3. Channel Strategy
    • 21.3.12. Cipla Inc (India)
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financials
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Strategy Overview
        • 21.3.12.6.1. Marketing Strategy
        • 21.3.12.6.2. Product Strategy
        • 21.3.12.6.3. Channel Strategy
    • 21.3.13. Lupin (India)
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financials
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Strategy Overview
        • 21.3.13.6.1. Marketing Strategy
        • 21.3.13.6.2. Product Strategy
        • 21.3.13.6.3. Channel Strategy
    • 21.3.14. Aurobindo Pharma (India)
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financials
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Strategy Overview
        • 21.3.14.6.1. Marketing Strategy
        • 21.3.14.6.2. Product Strategy
        • 21.3.14.6.3. Channel Strategy
    • 21.3.15. Sanofi (France)
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Sales Footprint
      • 21.3.15.4. Key Financials
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Strategy Overview
        • 21.3.15.6.1. Marketing Strategy
        • 21.3.15.6.2. Product Strategy
        • 21.3.15.6.3. Channel Strategy
    • 21.3.16. Fresenius SE & Co. KGaA (Germany)
      • 21.3.16.1. Overview
      • 21.3.16.2. Product Portfolio
      • 21.3.16.3. Sales Footprint
      • 21.3.16.4. Key Financials
      • 21.3.16.5. SWOT Analysis
      • 21.3.16.6. Strategy Overview
        • 21.3.16.6.1. Marketing Strategy
        • 21.3.16.6.2. Product Strategy
        • 21.3.16.6.3. Channel Strategy
    • 21.3.17. F. Hoffmann-La Roche Ltd (Switzerland)
      • 21.3.17.1. Overview
      • 21.3.17.2. Product Portfolio
      • 21.3.17.3. Sales Footprint
      • 21.3.17.4. Key Financials
      • 21.3.17.5. SWOT Analysis
      • 21.3.17.6. Strategy Overview
        • 21.3.17.6.1. Marketing Strategy
        • 21.3.17.6.2. Product Strategy
        • 21.3.17.6.3. Channel Strategy
    • 21.3.18. Takeda Pharmaceutical Company Limited (Japan)
      • 21.3.18.1. Overview
      • 21.3.18.2. Product Portfolio
      • 21.3.18.3. Sales Footprint
      • 21.3.18.4. Key Financials
      • 21.3.18.5. SWOT Analysis
      • 21.3.18.6. Strategy Overview
        • 21.3.18.6.1. Marketing Strategy
        • 21.3.18.6.2. Product Strategy
        • 21.3.18.6.3. Channel Strategy
    • 21.3.19. Abbott (US.)
      • 21.3.19.1. Overview
      • 21.3.19.2. Product Portfolio
      • 21.3.19.3. Sales Footprint
      • 21.3.19.4. Key Financials
      • 21.3.19.5. SWOT Analysis
      • 21.3.19.6. Strategy Overview
        • 21.3.19.6.1. Marketing Strategy
        • 21.3.19.6.2. Product Strategy
        • 21.3.19.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology